[1-Isopropyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [1-Isopropyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester
• 英文别名: (2-fluorophenyl) N-[2-methyl-8-(2-methyl-4,5-diphenylimidazol-1-yl)octan-3-yl]carbamate
• 化学式: C₃₂H₃₆FN₃O₂
• 分子量: 513.655
• InChiKey: HMJCRVRGZFQOMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-Isopropyl-7-(2-methyl-4,5-diphenyl-imidazol-1-yl)-heptanoic acid ethyl ester 在 sodium hydroxide 、 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 [1-Isopropyl-6-(2-methyl-4,5-diphenyl-imidazol-1-yl)-hexyl]-carbamic acid 2-fluoro-phenyl ester
  参考文献：
  名称：

  Novel inhibitors of fatty acid amide hydrolase

  摘要：

  A class of bisarylimidazole derivatives are identified as potent inhibitors of the enzyme fatty acid amide hydrolase (FAAH). Compound 17 (IC50 = 2 nM) dose-dependently (0.1-10 mg/kg, iv) potentiates the effects of exogenous anandamide (1 mg/kg, iv) in a rat thermal escape test (Hargreaves test), and shows robust antinociceptive activity in animal models of persistent (formalin test) and neuropathic (Chung model) pain. Compound 17 (20 mg/kg, iv) demonstrates activity in the formalin test that is comparable to morphine (3 mg/kg, iv), and is dose-dependently inhibited by the CB1 antagonist SR141716A. In the Chung model, compound 17 shows antineuropathic effects similar to high-dose (100 mg/kg) gabapentin. FAAH inhibition shows potential utility for the clinical treatment of persistent and neuropathic pain. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.009

文献信息

• Bisarylimidazolyl fatty acid amide hydrolase inhibitors
  申请人：——

  公开号：US20020188009A1

  公开（公告）日：2002-12-12

  The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.

  本发明涉及双芳基咪唑基衍生物和含有该类化合物的药物组合物，该组合物能抑制脂肪酸酰胺水解酶，适用于治疗疼痛，特别是神经病性疼痛、精神运动障碍、高血压、心血管疾病、进食障碍、恶心、艾滋病相关综合症、青光眼、炎症、牛皮癣或多发性硬化等疾病，以及其他通过抑制脂肪酸酰胺水解酶可治疗的疾病。
• USRE039634E1
  申请人：——

  公开号：——

  公开（公告）日：——
• EP1389107A4
  申请人：——

  公开号：EP1389107A4

  公开（公告）日：2005-10-12
• BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS
  申请人：Bristol-Myers Squibb Co.

  公开号：EP1389107A1

  公开（公告）日：2004-02-18
• Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
  申请人：Piomelli Daniele

  公开号：US20080103209A1

  公开（公告）日：2008-05-01

  Compositions and methods for treating noninflammatory pain, including but not limited to, neuropathic pain by using peroxisome proliferator activated receptor a (PPARa) agonists to treat a subject having such pain are described. The agonists may be used with additional therapeutic agents such as an inhibitor of fatty acid amide hydrolase or a cannabinoid CB1 or CB2 cannabinoid receptor agonist.